|
Sign In to gain access to subscriptions and/or personal tools.
|
Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS
M Chen
University of Maryland School of Medicine, Baltimore, MD 21201, USA
B Gran
Neuroimmunology Branch, NINDS, National Institutes of Health, Bethesda, MD 20892, USA
K Costello
University of Maryland School of Medicine, Baltimore, MD 21201, USA
K Johnson
University of Maryland School of Medicine, Baltimore, MD 21201, USA
R Martin
Neuroimmunology Branch, NINDS, National Institutes of Health, Bethesda, MD 20892, USA
S Dhib-Jalbut
University of Maryland School of Medicine, Baltimore, MD 21201, USA, Baltimore VA Medical Center, Baltimore, MD 21201, USA
Glatiramer acetate (GA) is an approved treatment for multiple sclerosis (MS). The proposed mechanism of action is the induction of GA-specific T cells characterized by protective anti-inflammatory Th2 response. We tested this hypothesis in 11 MS patients treated with GA from 1-19 months. Interferon-g and IL-5 (markers of Th1 and Th2 responses respectively) were assayed by ELISA in GA-specific T-cell lines (TCL) supernatants. Th1/Th2 bias was defined based on the ratio of IFN- /IL-5 secretion. Fifty-eight pre-treatment, and 75 on-treatment GA-specific TCL were generated. On-treatment mean IL-5 levels in GA-TCL increased significantly, whereas those for IFN-g were markedly reduced. Consequently, the ratio of IFN-/IL-5 also shifted in favor of a Th2 response. The percentage of GA-TCL classified as Th1 was decreased, whereas those classified as Th2 increased on-treatment as compared to pre-treatment. Some GA-specific TCL, (approximately 25%) generated during treatment secreted predominantly IL-5 in response to MBP and the immunodominant MBP peptide 83-99, indicating that these crossreactive antigens can act as partial agonists for GA-reactive TCL. These results strongly suggest that the mechanism of action of GA in MS involves the induction of crossreactive GA-specific T cells with a predominant Th2 cytokine profile.
Key Words: multiple sclerosis • glatiramer acetate • Copaxone® • Copolymer-1 • immune deviation
Multiple Sclerosis, Vol. 7, No. 4,
209-219 (2001)
DOI: 10.1177/135245850100700401
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
V. Skihar, C. Silva, A. Chojnacki, A. Doring, W. B. Stallcup, S. Weiss, and V. W. Yong
Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate
PNAS,
October 20, 2009;
106(42):
17992 - 17997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Vollmer, H Panitch, A Bar-Or, J Dunn, M. Freedman, S. Gazda, D Campagnolo, F Deutsch, and D. Arnold
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
Multiple Sclerosis,
June 1, 2008;
14(5):
663 - 670.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R.M. Valenzuela, K. Costello, M. Chen, A. Said, K.P. Johnson, and S. Dhib-Jalbut
Clinical response to glatiramer acetate correlates with modulation of IFN-{gamma} and IL-4 expression in multiple sclerosis
Multiple Sclerosis,
July 1, 2007;
13(6):
754 - 762.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar
Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis.
J. Immunol.,
June 1, 2006;
176(11):
7119 - 7129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hong, N. Li, X. Zhang, B. Zheng, and J. Z. Zhang
Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3
PNAS,
May 3, 2005;
102(18):
6449 - 6454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Boska, T. B. Lewis, C. J. Destache, E. J. Benner, J. A. Nelson, M. Uberti, R. L. Mosley, and H. E. Gendelman
Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease
J. Neurosci.,
February 16, 2005;
25(7):
1691 - 1700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sela and E. Mozes
Therapeutic vaccines in autoimmunity
PNAS,
October 5, 2004;
101(suppl_2):
14586 - 14592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Benner, R. L. Mosley, C. J. Destache, T. B. Lewis, V. Jackson-Lewis, S. Gorantla, C. Nemachek, S. R. Green, S. Przedborski, and H. E. Gendelman
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
PNAS,
June 22, 2004;
101(25):
9435 - 9440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K P Johnson, B R Brooks, C C Ford, A D Goodman, R P Lisak, L W Myers, A A Pruitt, M A Rizzo, J W Rose, L P Weiner, et al.
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
Multiple Sclerosis,
December 1, 2003;
9(6):
585 - 591.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. H. Salama, J. Hong, Y. C. Q. Zang, A. El-Mongui, and J. Zhang
Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis
Brain,
December 1, 2003;
126(12):
2638 - 2647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Weir, C. C. A. Bernard, and B. T. Backstrom
IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis
Int. Immunol.,
November 1, 2003;
15(11):
1283 - 1289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Jansson, J Ernerudh, M Kvarnstrom, C Ekerfelt, and M Vrethem
Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-b1a or glatiramer acetate compared with untreated patients
Multiple Sclerosis,
October 1, 2003;
9(5):
440 - 445.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S Dhib-Jalbut, M Chen, K Henschel, D Ford, K Costello, and H Panitch
Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis
Multiple Sclerosis,
December 1, 2002;
8(6):
485 - 491.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Dhib-Jalbut
Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
Neurology,
April 23, 2002;
58(90084):
S3 - 9.
[Abstract]
[Full Text]
|
|
|
|
|
